PTGS2 and breast cancer: 1,25(OH)2D3 administration suppress the expression of cyclooxygenase-2 (which catalyzes PG synthesis) and increases the expression of 15-hydroxyprostaglandin dehydrogenase (which catalyzes PG degradation) resulting in overall reduction in PGs levels in prostate and breast cancer cells [112,113].